SCHEMBL4227086

SCHEMBL4227086

N[C@@H]1CCN(CC2CCCCC2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.45
ADRA2C P18825 1/20 0.45
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 1/20 0.42
APEX1 P27695 1/20 0.42
DPP4 P27487 2/20 0.39
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
ACHE P22303 1/20 0.36
OPRM1 P35372 2/20 0.36
OPRK1 P41145 2/20 0.36
OPRL1 P41146 2/20 0.36
HSD11B1 P28845 1/20 0.36
OPRD1 P41143 1/20 0.36
CYP19A1 P11511 2/20 0.35
MMP1 P03956 3/20 0.35
MMP9 P14780 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3816674 0.85 CYP3A4 (0.38) CHRM5ADRA2CCYP3A4TSHRTDP1
SCHEMBL4702124 0.85 CYP3A4 (0.38) CHRM5ADRA2CCYP3A4TSHRTDP1
SCHEMBL2687448 0.82 CYP3A4 (0.40) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL8506958 0.78 CHRM5 (0.45) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL892512 0.74 CHRM5 (0.41) CHRM5ADRA2C
Trifluoroacetic Acid SCHEMBL3818811 0.74 DPP4 (0.34) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL6258023 0.73 CYP3A4 (0.45) CYP3A4TSHRTDP1MAPTAPEX1
SCHEMBL318757 0.72
SCHEMBL9255336 0.72
SCHEMBL16190279 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101001851-B Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC 2011-04-20 CN disclosed
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
CN-101001851-A Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC (JP) 2007-07-18 CN disclosed
EP-1776357-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) Astellas Pharma Inc. (JP) 2007-04-25 EP disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed
WO-2006016680-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) ASTELLAS PHARMA INC. (JP) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 CHRM5 4339/4885ADRA2C 2005/4885CYP3A4 2924/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 CHRM5 4349/4885ADRA2C 1890/4885CYP3A4 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.